Pivotal Therapeutics Reports 1st Quarter 2012 Results
28 Maio 2012 - 5:31PM
Pivotal Therapeutics Inc. (OTCQX:PVTTF)
(CNSX:PVO), a specialty pharmaceutical company with a focus on the
treatment of cardiovascular disease, today announced its financial
results and operational highlights for the three months ended ended
March 31, 2012. All dollar amounts referenced herein are in
Canadian dollars unless otherwise stated.
For the quarter ended March 31, 2012 the company reported a loss
of $831,090, or $0.01 per common share, compared with a loss of
$947,912, or $0.02 per common share for the three months ended
March 31, 2011. At March 31, 2012, Pivotals' cash position totaled
$554,797, compared with $1,586,653 million at December 31,
2011. The decrease in cash during the three months ended March
31, 2012, is due primarily to the expansion of commercial selling
efforts of Vascazen™, costs associated with the
filing of US and international patents and an increase in costs
associated with being listed on the Canadian National Stock
Exchange and the OTCQX exchange in the US.
"We reached an important milestone with the initiation of sales
of Vascazen™, our prescription medical food
formulated to meet the dietary Omega-3 deficient needs of patients
with cardiovascular disease," stated CEO Eugene
Bortoluzzi.
"The launch of Vascazen™ is the result of
collaborative scientific, trademark and commercial efforts that we
believe will be transformative for the company," added Pivotal's
President, Rachelle MacSweeney.
The unaudited consolidated financial statements, accompanying
notes and Management's Discussion and Analysis for the three months
ended March 31, 2012, will be accessible on Pivotal's website at
www.pivotaltherapeutics.us and on SEDAR (www.sedar.com).
Highlights for 2012:
- February 22, 2012 – the Company filed five international patent
filings covering 142 countries;
- February 29, 2012 – the Company's presented at the 61st Annual
Scientific Session and Expo of the American College of
Cardiology;
- March 8, 2012 – Standard and Poor's Capital IQ Market Access
Program began coverage of the Company;
- April 3, 2012 - the Company began trading in the US on the OTC
Markets' QX Marketplace, under the symbol PVTTF;
- April 3, 2012 – the Company announced its 2011 financial
results;
- May 22, 2012 – the Company announced first prescription sales
in the United States.
Pivotal's Goals for 2012
- Further commercialization of
Vascazen™ in the US;
- Expansion of the sales & marketing team;
- Completion of clinical trials for
Vascazen™ and publication of
scientific data;
- Expansion of intellectual property portfolio;
- Investigation of international licensing opportunities;
- Expansion of product offerings;
- Increase capitalization of the company to accelerate its
growth.
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX:PVTTF) (CNSX:PVO)
specialty pharmaceutical company with a focus on the treatment of
cardiovascular disease and overall health. Pivotal
Therapeutics' lead product VASCAZENTM is a
prescription only medical food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease
through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA)
to levels associated with reduced risk of cardiovascular
complications.
VASCAZENTM is a >90% pure, proprietary
EPA:DHA fatty acid formulation, protected by a series of both
issued and pending US and foreign patents and commercialized by
prescription only. This unique formulation will provide the
cornerstone upon which a family of cutting edge combination
products, with efficacy across a broad spectrum of cardiac care,
will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA
fatty acid formulation commercialized for sale and distribution in
Canada for the maintenance of good health through elevating Omega-3
fatty acid levels. The unique formulation and dosage will be
available to patients and consumers who realize the health benefits
of Omega-3 supplementation with a quality product.
Disclosure Notice
The information contained in this document is as of May 28,
2012. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by
the use of words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe",
"project", "potential", and similar expressions with any discussion
of future operating or financial performance or events. In
particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to
compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance;
risks relating to the Company's ability to maintain its CSNX
listing. Forward-looking statements speak only as of the date made
and are not guarantees of future performance. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments.
CONTACT: Investor Relations Contact:
Timothy J. Ryan
Managing Director
Phone: 212-242-7777
E-Mail: tryan@shorehamgroupllc.com
The Shoreham Group, LLC
www.shorehamgroupllc.com
Company Contact:
Rachelle MacSweeney
President
Phone: 905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us
Pivotal Therapeutics Inc.
www.pivotaltherapeutics.us
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024